论文部分内容阅读
应用免疫组化技术对乳腺导管上皮轻中度非典型增生(轻中度组,Ⅱ组)23例、重度非典型增生(重度组,Ⅲ组)33例、浸润性导管癌(癌组,Ⅳ组)40例和正常乳腺(正常组,Ⅰ组)20例进行bcl-2基因蛋白产物的检测。结果:1.以上4组bcl-2蛋白的阳性表达率分别为100％,81.82％和77.50％,100％,四组间比较差异有显著性(P<0.05)。2.Ⅰ组阳性表达率显著地高于Ⅳ组(P<0.05)。3.Ⅲ组阳性表达率与Ⅰ组相同,皆为100％。4.Ⅲ组阳性表达率显著低于Ⅱ组(P<0.05),稍高于Ⅳ组,两者间差异无显著性(P>0.05)。提示:乳腺导管上皮重度非典型增生bcl-2蛋白的表达与癌的关系密切,其检测可能作为评估乳腺导管上皮重度非典型增生恶变潜能的一个参考指标。
Immunohistochemical technique for 23 cases of mild-moderate atypical hyperplasia of mammary duct epithelium (mild-moderate group, group II), 33 cases of severe dysplasia (heavy group, group III), invasive ductal carcinoma (cancer group, IV) Group) 40 cases and normal breast (normal group, group I) 20 cases of bcl-2 gene protein product detection. Results: 1. The positive expression rates of bcl-2 protein in the above four groups were 100%, 81.82%, 77.50% and 100%, respectively. There was significant difference between the four groups (P<0.05). 2. The positive rate of I group was significantly higher than that of IV group (P<0.05). 3. The positive expression rate of group III was the same as that of group I, all being 100%. The positive expression rate in group III was significantly lower than that in group II (P<0.05), and slightly higher than in group IV. There was no significant difference between the two groups (P>0.05). Tip: The expression of bcl-2 protein in severe atypical hyperplasia of mammary ductal epithelium is closely related to cancer, and its detection may serve as a reference index for evaluating the malignant potential of severe atypical hyperplasia of mammary duct epithelium.